Archives
-
CHK1 Inhibition in Breast Cancer by ER/PR Status
2026-09-10
The reference study shows that CHK1 inhibition cannot be applied uniformly across breast cancer: it enhances adriamycin sensitivity in ER−/PR−/HER2− disease but has mainly single-agent activity in ER+/PR+/HER2− models. By combining receptor-stratified functional assays with transcriptome and bioinformatics analyses, the work connects these divergent responses to distinct cell-cycle and apoptosis pathways.
-
NSP15 Inhibitor Screening: Thymopentin and Oleuropein
2026-09-09
A 2021 structure-based study screened a natural-product library against the SARS-CoV-2 endoribonuclease NSP15 and identified thymopentin and oleuropein as the leading predicted binders. Molecular dynamics supported stable protein–ligand complexes, but the findings remain computational and require biochemical, cellular, and pharmacological validation.
-
Gastrodin, AT1 Signaling, and Reactive Astrocytes
2026-09-09
The reference study connects microglia-derived inflammatory signals with astrocytic renin–angiotensin system activity, SIRT3, phenotype markers, and neurotrophic mediators. Its use of AT1 pharmacological inhibition positions Azilsartan as a mechanistic tool for testing how AT1 signaling contributes to reactive astrocyte responses, while also highlighting the limits of translating conditioned-medium findings to intact disease models.
-
Z-VAD-FMK: A Cell-Death Pathway Dissection Guide
2026-09-08
Z-VAD-FMK is more than a broad apoptosis blocker: it is a causal tool for separating caspase-dependent death from alternative cell-death routes. This guide connects its mechanism and assay design to emerging MLKL-centered necroptosis research.
-
Pyridostatin TFA: G-Quadruplex Research Workflows
2026-09-08
Use Pyridostatin TFA to connect G-quadruplex stabilization with telomere dysfunction, cancer-cell phenotyping, and structure-aware assay design. This guide combines practical dosing, orthogonal validation, and cautious extension into RNA G-quadruplex and TDP-43 research.
-
Octyl-α-ketoglutarate for HIF-1α Assays
2026-09-07
Octyl-α-ketoglutarate is a cell-permeable α-ketoglutarate tool for testing whether impaired prolyl hydroxylase activity links TCA cycle dysfunction to HIF-1α stabilization. This workflow combines metabolic rescue, hypoxia-pathway readouts, and IDH-focused controls to distinguish substrate limitation from broader cellular stress.
-
Annular Microneedles for Glaucoma Mitochondrial Therapy
2026-09-07
The reference study develops an annular sector-shaped microneedle patch for localized co-delivery of nicotinamide and an Nmnat1-encoding lipid nanoparticle to the trabecular meshwork. In human trabecular meshwork cell models and dexamethasone-induced glaucoma mice, this combination improved NAD+ biosynthetic support, reduced mitochondrial dysfunction, lowered intraocular pressure, and alleviated fibrosis.
-
Palonosetron for Chemotherapy-Induced Nausea and Vomiting
2026-09-05
This 2013 review explains why palonosetron, a long-acting 5-HT3 receptor antagonist, improved prevention of delayed chemotherapy-induced nausea and vomiting, particularly after moderately emetogenic chemotherapy. Its value lies in connecting receptor pharmacology, clinical evidence, and guideline positioning while identifying unresolved needs in multi-day chemotherapy and breakthrough symptom management.
-
11β-HSD1 Inhibition in Liver Fibrosis
2026-09-04
A 2025 mouse study identifies a coordinated antifibrotic mechanism in which 11β-HSD1 inhibition lowers local cortisol, suppresses Notch signaling, and increases natural killer cell activity. The work connects metabolic hormone regulation with immune-mediated clearance of activated hepatic stellate cells, while also highlighting the limits of extrapolating a thioacetamide model to human MASH.
-
Nelfinavir Mesylate in HIV and Ferroptosis Assays
2026-09-04
Nelfinavir Mesylate supports two complementary research directions: quantitative HIV-1 protease inhibition and mechanistic studies of DDI2–NFE2L1 proteostasis during ferroptosis. This guide translates its published potency, formulation properties, and reference-study findings into practical assay workflows and troubleshooting strategies.
-
Lamotrigine: Sodium Channels, 5-HT and BBB Research
2026-09-03
Lamotrigine is a research-use anticonvulsant compound identified as 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine. Its reported sodium-channel and serotonin-pathway activities support epilepsy, CNS permeability, and cardiac sodium current modulation studies, but the supplied evidence does not establish clinical efficacy or lamotrigine-specific BBB penetration.
-
Pam3CSK4 TFA for Reliable TLR1/2 Assays
2026-09-03
Learn how Pam3CSK4 TFA (SKU B5662) can make TLR1/2 stimulation more interpretable in cell viability, proliferation, cytotoxicity, and cytokine assays. This scenario-based guide connects formulation control, assay compatibility, protocol optimization, and recent maternal-neonatal immunology findings.
-
PMSF Workflows for Protein Extraction and Western Blotting
2026-09-02
Phenylmethanesulfonyl fluoride (PMSF) provides fast, irreversible protection against serine proteases during tissue, cell, and trophoblast protein extraction. This practical guide connects PMSF for Western blot sample preparation with assay design, epitranscriptomic studies, and troubleshooting limits.
-
Mitoxantrone HCl: Mechanism and Research Use
2026-09-02
Mitoxantrone HCl is a DNA topoisomerase II inhibitor that disrupts DNA cleavage and ligation and can produce double-strand DNA damage. Recent evidence also identifies mitoxantrone as an allosteric modulator of the ERα DBD-LBD interface, expanding its value for cancer biology and resistance research.
-
(+)-Bicuculline: Practical Lab Workflow
2026-09-01
(+)-Bicuculline (SKU N1592) provides a controlled way to reduce GABAA receptor-mediated inhibition when researchers are dissecting synaptic transmission, the GABAergic signaling pathway, or synaptic NMDA receptor signaling modulation. This guide covers dissolution, storage, controls, and interpretation; the compound is for research use only and should not be used for diagnostic, clinical, or therapeutic purposes.